Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Trial Profile

Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Gemcitabine (Primary) ; Lenalidomide (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms LENAGEM-PANC
  • Most Recent Events

    • 26 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jun 2012 Company added in the association field as reported by EudraCT.
    • 02 Mar 2012 Additional lead trial centres, lead trial investigators and Celgene Corporation as company identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top